




The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 6.4% points. The greatest weakness of Provectus Biopharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 167% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	1,365
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,017
Liabilities, Non-Current	25
Other Assets	72
Other Compr. Net Income	-24
Other Expenses	0
Other Liabilities	0
Other Net Income	-201
Other Revenues	558
Property and Equipment	12
Research and Development	1,749
Selling, General and Administrative Expense	1,710

Output Variable	Value in 1000 USD
Assets	1,449
Liabilities	9,042
Expenses	3,459
Revenues	558
Stockholders Equity	-7,593
Net Income	-3,102
Comprehensive Net Income	-3,114
BaseVar	7,366
ECR before LimitedLiability	-375%
Economic Capital Ratio	46%